ClinicalTrials.gg
CompletedNCT04041648Updated Aug 5, 2025

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

A Phase 1 interventional study of L606 (Liposomal Treprostinil) Inhalation Solution 51ug and L606 Inhalation System in Pulmonary Arterial Hypertension, sponsored by Pharmosa Biopharm Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Pharmosa Biopharm Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Sep 2019, 7 years 1 month ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Nov 2018, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
11th of 44
52 · median 32
Started
2018
with 2 others
Phase 1
9 of 44
none open now
Registered
39th of 44
by date
Lead sponsor
1 of 44
Pharmosa Biopharm Inc.

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 11th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 1, and was the 39th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.

Read the detailed description

L606 (Liposomal Treprostinil) Inhalation Solution and dedicated inhalation system is developed by Pharmosa Biopharm Inc. intended to improve the inconvenience, as one of the greatest impediments to patient satisfaction to current inhaled treprostinil therapy. Pharmosa's liposomal technology offers sustained release of treprostinil which enable bid treatment instead of conventional qid treatment offered by current inhaled treprostinil therapy for treatment of patients with PAH (WHO Group 1).

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, of any race, 18 to 50 years of age, inclusive, at Screening.
  2. between 18.5 and 32.0 kg/m2, inclusive, at Screening.
  3. In good health, determined by no findings from medical history, physical examination, 12 lead , vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening or Check in as assessed by the Investigator (or designee).
  4. Ability of the subject to generate spirometry according to minimum ATS/ERS guidance criteria.
  5. Females will not be pregnant or lactating, and females of and males will agree to use as detailed in Section 6.6.
  6. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  7. Agree to abstain from consuming alcohol from 72 hours prior to Check-in.
  8. Agree to refrain from strenuous exercise from 7 days prior to Check-in.
  9. Agree to abstain from consuming foods and beverages containing poppy seeds, grapefruit, or Seville oranges from 7 days prior to Check-in.
  10. Agree to abstain from consuming caffeine-containing foods and beverages from 48 hours prior to Check-in.
  11. Agree to abstain from consuming carbonated drinks (including sparkling water and soda) from 48 hours prior to Check-in and until end of study.

Exclusion criteria

Exclusion Criteria:

  1. abnormalities identified during Screening, physical examination, 12 lead , or laboratory examinations.
  2. Clinically significant history of hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, genitourinary, and/or musculoskeletal disease, glaucoma, psychiatric disorder, or any other chronic disease, whether controlled by medication or not.
  3. History of anaphylaxis, significant , intolerance, or allergy to any drug compound, food, or other substance, unless deemed not clinically significant by the Investigator (or designee).
  4. History of postural hypotension, unexplained syncope, or hypertension.
  5. History of asthma, (COPD), or reactive airways conditions or findings consistent with asthma or COPD on spirometry testing.
  6. Blood pressure \<90 mmHg systolic or \<50 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
  7. Blood pressure >150 mmHg systolic or >90 mmHg diastolic after supine for 5 minutes at Screening or Check in upon repeat testing.
  8. Pulse rate >100 bpm after supine for 5 minutes at Screening or Check-in upon repeat testing.
  9. Have a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs. Cholecystectomy is permitted if done at least 10 days before enrollment.
  10. Use tobacco- or nicotine-containing products within 6 months prior to Check-in, or have a history of >1 pack cigarettes daily use over multiple years of smoking.
  11. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.
  12. Have a history of alcohol abuse or a history of or current impairment of organ function reasonably related to alcohol abuse.
  13. Have a history of or current evidence of abuse of licit or illicit drugs or a positive urine screen for drugs of abuse.
  14. Alcohol consumption of >21 units per week. One unit of alcohol equals 12 oz (360 mL) beer, 1.5 oz (45 mL) liquor, or 5 oz (150 mL) wine.
  15. Positive urine drug screen (including alcohol and cotinine) at Screening and/or Check-in.
  16. Positive hepatitis panel and/or positive test at Screening.
  17. Participation in a clinical study involving administration of an drug (new chemical entity) within 30 days prior to Check-in.
  18. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's Wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  19. Use or intend to use any prescription medications/products within 14 days prior to Check-in with the exception of hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine , unless deemed acceptable by the Investigator (or designee).
  20. Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
  21. Use or intend to use any nonprescription medications/products or herbal supplements within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee). Use of nonsteroidal anti inflammatory drugs or aspirin is prohibited within 14 days prior to Check-in.
  22. Receipt of blood products within 2 months prior to Check-in.
  23. Donation of blood, plasma, and , or the loss of a significant volume of blood (>450 mL) within 6 weeks prior to Screening.
  24. Poor peripheral venous access.
  25. Have a history of bleeding problems or abnormal bleeding tendencies.
  26. Platelet or coagulation factor levels below the lower limit of normal, unless considered not clinically significant by the Investigator.
  27. Have previously completed or withdrawn from this study or any other study investigating treprostinil, and have previously received the investigational product.
  28. History of any recent infection within 2 weeks of Check-in.
  29. In the opinion of the Investigator (or designee), should not participate in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Placebo comparator
    placebo

    placebo group

    Device: L606 Inhalation System · Other: Placebo Solution

  • Experimental
    L606 Liposomal inhalation solution

    Liposomal inhalation solution

    Drug: L606 (Liposomal Treprostinil) Inhalation Solution 51ug · Device: L606 Inhalation System

Interventions

  • Single ascending dose

    Also known as: Drug: L606 (Liposomal Treprostinil) Inhalation Solution

  • DeviceL606 Inhalation System

    Single ascending dose

    Also known as: Device: L606 Inhalation Solution

  • OtherPlacebo Solution

    Single ascending dose

06

What researchers measure

Primary outcomes

  1. The number of treatment-emergent adverse events for L606 and placebo, including abnormal laboratory events

    Frequency, severity and seriousness of adverse events (AE) including physical examination, incident of laboratory abnormalities, 12-lead ECG parameter and vital sign assessment

    Time frame: From Pre-dose to Day 10

Secondary outcomes

  1. AUC0-2hr

    area under curve from time zero to 2 hours postdose

    Time frame: From pre-dose to 24 hours post dose

  2. AUC0-4hr

    AUC from time zero to 4 hours postdose

    Time frame: From pre-dose to 24 hours post dose

  3. AUC0-8hr

    area under curve from time zero to 8 hours postdose

    Time frame: From pre-dose to 24 hours post dose

  4. AUC0-12hr

    area under curve from time zero to 12 hours postdose

    Time frame: From pre-dose to 24 hours post dose

  5. AUC0-24hr

    area under curve from time zero to 24 hours postdose

    Time frame: From pre-dose to 24 hours post dose

  6. AUC0-tlast

    AUC from time zero to the time of the last quantifiable concentration

    Time frame: From pre-dose to 24 hours post dose

  7. AUC0-∞

    area under curve from time zero to infinite

    Time frame: From pre-dose to 24 hours post dose

  8. Cmax

    maximum plasma concentration

    Time frame: From pre-dose to 24 hours post dose

  9. tmax

    time to Maximum Plasma Concentration

    Time frame: From pre-dose to 24 hours post dose

  10. t1/2

    time to half-life

    Time frame: From pre-dose to 24 hours post dose

  11. CL/F

    apparent total plasma clearance

    Time frame: From pre-dose to 24 hours post dose

  12. Vz/F

    apparent volume of distribution during terminal phase

    Time frame: From pre-dose to 24 hours post dose

07

Study locations

1 site
  • PPD
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2019, 10 months.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 10 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2019
First posted
Aug 1, 2019
StartActual
Nov 9, 2018
Primary completionActual
Sep 20, 2019
CompletionActual
May 12, 2020
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04041648
Lead sponsor
Pharmosa Biopharm Inc.
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Nov 9, 2018
Primary completion
Sep 20, 2019
Completion
May 12, 2020
Last update
Aug 5, 2025

Study contacts

Thomas L Hunt, MD, PhD
principal investigator · Pharmosa Biopharm Inc.PPD

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion